<DOC>
	<DOC>NCT01340482</DOC>
	<brief_summary>The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH). A Bone Substudy will evaluate the effects of single-blind KRN23 versus Placebo on bone mineral density and bone quality.</brief_summary>
	<brief_title>A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
	<mesh_term>Hypophosphatemia</mesh_term>
	<criteria>Main 1. 18 years or older 2. Clinical diagnosis of XLH 3. TmP/GFR &lt; 2.0 mg/dL 4. GFR â‰¥60 mL/min 5. Corrected Ca &lt;10.8 mg/dL 6. A willingness to utilize adequate contraception and not become pregnant[or to have their partner(s) become pregnant] during the study 7. Additional inclusion criteria apply Main 1. Have any sign of active infectious disease or have had an infection requiring treatment with antibiotics within 3weeks of Screening 2. History of known immunodeficiency 3. Pregnant or lactating females subjects or female planning to be become pregnant during the study 4. Receipt of a live (attenuated) vaccine (except for influenza vaccines) within 3months of Screening, and/or during the study 5. Use of pharmacologic vitamin D metabolite or its analog, phosphate, calcimimetics, and ingestion of aluminum hydroxide antacids within 10days prior to Screening and/or dosing 6. Use of any supplement containing phosphate, calcium and/or vitamin D within 10days prior to Screening and/or dosing 7. Condition which could present a concern for either the subject's safety or difficulty with data interpretation 8. Additional exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>XLH</keyword>
</DOC>